# US 2023/0057094 A1 · Pharmaceutical composition containing a surfactant and natural plant extracts for preventing and treating coronavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057094 A1
- Document ID: US20230057094A1
- Status: Published application
- Kind: A1
- Application number: 17/759,123
- Filed: 2020-08-29
- Published: 2023-02-23
- Earliest claimed: 2020-08-29
- Inventors: Rosa Maria Portillo Rosado
- Web page: https://patentgrep.com/patent/US20230057094A1

## CPC

- A61K 38/014: {from connective tissue peptides, e.g. gelatin, collagen}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 36/22: Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
- A61K 36/288: Taraxacum (dandelion)
- A61K 36/36: Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/79: Schisandraceae (Schisandra family)
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and pharmaceutical forms for the treatment and prevention of coronavirus, which contain in its formulation non-hydrolyzed collagen as a surfactant with degreasing properties and natural active ingredients in the form of hydrolyzed powders of aqueous extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), oregano (Origanum vulgare), star anise (Lllicium verun) together with preservatives, as well as the obtaining and preparation procedures associated with the development of the different compositions and pharmaceutical forms.

## Claims

### Claim 1

A pharmaceutical composition for treating and preventing coronavirus a non-hydrolyzed collagen as a surfactant with degreasing properties together in addition to natural plants in the form of lyophilized powders of aqueous extracts dandelion (taraxacum officinale), anamú (petiveria alliacea), epazote (dysphania ambrosioides), oregano (origanum vulgare), star anise (Illicium verun), together with preservatives.

### Claim 2 (depends on 1)

The composition of claim 1, comprises:
non-hydrolyzed collagen
1% up to 35%
dandelion extract
5% up to 30%
anamu extract
3% up to 20%
epazote extract
3% up to 20%
oregano extract
5% up to 25%
star anise extract
1% up to 15%
sodium benzoate
0.25%
potassium sorbate
0.25%.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition is a hard gelatin capsule for oral administration and:
non-hydrolyzed collagen
25%
dandelion extract
20%
anamu extract
10%
epazote extract
15%
oregano extract
19.5%
star anise extract
10%
sodium benzoate
0.25%
potassium sorbate
0.25%.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition is a tea or infusion formulated in a bag or sack of porous paper, silk or nylon to be dissolved in hot water and comprises:
non-hydrolyzed collagen
30%
dandelion extract
15%
anamu extract
15%
epazote extract
17%
oregano extract
15%
star anise extract
7.50%
sodium benzoate
0.25%
potassium sorbate
0.25%.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition is a drinkable ampoule and comprises:
properly treated water
19.5%
non-hydrolyzed collagen
35%
dandelion Extract
10%
anamu Extract
8%
epazote Extract
12%
oregano extract
10%
star anise extract
5%
sodium benzoate
0.25%
potassium sorbate
0.25%.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is an intramuscular injectable solution and comprises:
properly treated water
18.5%
non-hydrolyzed collagen
24%
dandelion extract
13%
anamu Extract
18%
epazote Extract
8%
oregano extract
8%
star anise extract
8.51%
lidocaine
1.8%
benzoic Acid
0.17%
ascorbic acid
0.02%.

### Claim 7 (depends on 1)

A method for obtaining active ingredients from a product comprising the steps of:
i. inspecting, classifying, and approving of a raw materials;
ii. optionally separating shell and seeds of the raw material;
iii. mixing the raw materials with temperature control at 96° C. (205° F.), and stirring every 5 minutes;
iv. filtering and adding preservatives;
v. homogenized spraying of the active ingredients and preservatives; and
vi. preparation of the pharmaceutical composition of claim 1, in the form of a capsule, a tea, drinkable ampoules, or an intramuscular injectable solution.

### Claim 8 (depends on 3, 4, 5, 6)

A method for treating and preventing coronavirus, the step of:
administering to a person in need of the hard gelatin capsule of claim 3; or
administering to a person in need of the the tea or infusion of claim 4; or
administering to a person in need of the drinkable ampoules of claim 5; or
administering to a person in need of the intramuscular injectable solution of claim 6.

### Claim at position 9

9-11. (canceled)